COMP <GO>
VRTX vs BMY // NET PROFIT MARGIN
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. Bristol-Myers Squibb Company (NYSE) • 15-METRIC TALLY: VRTX 10
— BMY 4
▲ NET PROFIT MARGIN LEADER: VRTX
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
net-margins
32.90%
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
net-margins
14.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. BMY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | BMY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 71.10% | +15.10 | VRTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 13.30% | +6.70 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 16.3x | +13.30 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 10.24% | -7.91 | BMY | /fcf-yield <GO> |
| Operating Margin | 34.80% | 17.90% | +16.90 | VRTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 32.90% | 14.60% | +18.30 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | -0.20% | +9.10 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 4.02% | -4.02 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 2.24 | +11.62 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 50.4 | +7.30 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.98 | +0.04 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 16.6x | +15.60 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $125.40B | $11.47B | VRTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | BMY REV | VRTX GROSS % | BMY GROSS % | VRTX FCF | BMY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $48.19B | 86.2% | 71.1% | $3.19B | $12.85B |
| FY 2024 | $11.02B | $48.30B | 86.1% | 71.1% | -$790.3M | $13.94B |
| FY 2023 | $9.87B | $45.01B | — | — | $3.09B | $11.83B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
BMY // BETA 0.98